Viyash Scientific Limited FY26 Performance and Corporate Developments
Financial Performance Highlights
Viyash Scientific Limited reported exceptional financial results for FY 2025-26 with consolidated revenue growth of 13.8% to ₹34,203.1 million and net profit surging 663% to ₹2,246.5 million. EBITDA showed remarkable improvement at ₹7,025 million (59.6% YoY growth) with margins expanding to 20.5% from 14.6% previous year. The standalone entity reported revenue of ₹13,820.58 million with net profit of ₹758.67 million.
Composite Scheme of Amalgamation
The company successfully completed a composite scheme of amalgamation with Viyash Life Sciences Private Limited and its subsidiaries, sanctioned by NCLT Hyderabad on November 18, 2025. The amalgamation, effective from December 16, 2025 with appointed date of April 1, 2025, resulted in issuance of 181,921,827 equity shares and 20,341,257 warrants. This strategic consolidation created a capital reserve of ₹454.22 million and significantly strengthened the company's balance sheet with total assets reaching ₹46,283.87 million.
Operational and Business Performance
The company demonstrated strong performance across business segments with formulations revenue growing 18% to ₹18,657 million and API revenue increasing 8% to ₹14,906 million. Geographic performance was robust with Europe showing 19% growth (₹6,682 million), Emerging Markets 23% growth (₹6,305 million), and India 22% growth (₹1,405 million). The company maintained 16 manufacturing facilities (10 USFDA approved) with total API capacity of 2,546 KL across 10 plants in India.
Strategic Initiatives and R&D Focus
Key developments included the successful companion animal business launch in India through Boehringer Ingelheim partnership, EU GMP certification for Spanish manufacturing plant, and new injectable R&D center at Ankara University. R&D investments yielded 19 new product launches, 21 regulatory approvals, and 19 APIs in pipeline. The company maintained 250+ scientists including 20+ PhDs and filed 175+ patents globally with 55+ patents granted.
ESG and Sustainability Performance
Viyash Scientific demonstrated strong ESG commitment with SBTi validation for near-term and long-term emission reduction targets in June 2025. Environmental performance included 82.8 Terajoules renewable power consumption, 6,720 kL water savings (2.46% of total consumption), and ISO 14001:2015 and ISO 45001:2018 certifications across facilities. Social metrics showed 2,568 permanent employees with 11% women in workforce and 100% training coverage on safety, ethics, and compliance.
Corporate Governance and Board Structure
The board maintained strong governance with 7 directors (3 Executive, 3 Independent, 1 Non-Executive Non-Independent) including Dr. Kamal Sharma as Independent Chairman. Key committees were effectively structured with Mr. Milind Sarwate chairing Audit and Nomination committees. The company received credit rating upgrades with India Ratings upgrading to IND AA- (Stable) from IND A (Positive) and ICRA assigning [ICRA] AA- (Stable).
41st Annual General Meeting
The company issued notice for its 41st AGM scheduled for August 11, 2026 through video conferencing, with cut-off date for voting eligibility set as August 4, 2026. The board recommended no dividend for FY26 in line with the company's dividend distribution policy, prioritizing growth investments over distributions.
Forward Outlook and Growth Priorities
The company is focused on three strategic growth priorities: companion animal health expansion in Europe and India, CDMO platform development leveraging API strengths, and geographic extension of existing formulations portfolio. R&D remains a key investment area with focus on complex generics, oncology products, and differentiated APIs, positioning the company for sustained growth in the global pharmaceuticals market.